Primary renal diffuse large B-Cell lymphoma causing haemodialysis-dependent nephromegaly in a child

South, Andrew M.

doi:10.1136/bcr-2018-226328

Cited by 10 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11,14 Both anemia and polycythemia have been reported in PRNHL as uncommon findings. 23,66,70 There were four patients who have been complicated with IVC (inferior vena cava) thrombosis. 26,35,66,71 In all of the 83 patients reported as PRNHL, the primary presentation has been in kidney, but in 17 patients, simultaneous involvement of other organs have been discovered after the kidney, which have been in Meninges, 3,6 Central nervous system, 14,20,60 bone, 11 lymph-node, 22,27,32,62,71,72 adrenal and liver, 35 pleura, 40 orbit, 21 thyroid, 52 and bone marrow involvement.…”

Section: Resultsmentioning

confidence: 99%

“…PET is also useful in monitoring response to therapy. [70][71][72][73][74][75][76] It's worthy to note again, that final diagnosis cannot be made without tissue diagnosis and histopathology is the gold standard for the diagnosis of PRNHL. 11 Immunohistochemistry is also necessary to find out about the type of NHL which is very important to select the therapeutic chemotherapy regimen.…”

Section: Discussionmentioning

confidence: 99%

“…16 In the cases with pre-operative diagnosis of NHL, no nephrectomy has been recommended especially in high grade NHLs. 70 In the patients with underlying diseases such as diabetes or immune deficiencies, rapid worsening of the renal function justifies thinking of diagnosis other than RCC. 9 Overall, regarding to most of the current reports and studies, treatment of PRNHL is different according to the type and grade of NHL.…”

Section: Discussionmentioning

confidence: 99%

“…Due to the low incidence of PRNHL, randomized controlled trials (RCT) have not been developed to evaluate the best treatment option, 60 however overall the therapeutic regimen for PRNHL depends on the type of lymphoma (according to the tissue diagnosis and immunohistochemistry results) which is most commonly B cell (diffuse large B cell type). 2 …”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Primary renal non-Hodgkin’s lymphoma: A narrative review of literature

2021

View full text Add to dashboard Cite

Renal involvement by Non-Hodgkin’s lymphoma (NHL) is very rare, and involvement of the kidney as the primary site of NHL (PRNHL) is much more uncommon. Gold standard for the diagnosis of PRNHL is histology and imaging modalities although helpful are not specific. Nephrectomy has been mostly recommended for low grade lymphomas, and for high grade PRNHLs, chemotherapy without nephrectomy has been recommended as the treatment of choice. This tumor is aggressive with poor prognosis. This poor prognosis is partly because of delayed diagnosis and partly because of unnecessary surgeries, so it should be kept in mind, especially in bilateral renal tumors with unusual imaging characteristics, to take a tissue biopsy before nephrectomy. In this review, we will discuss all the detailed aspects of clinical, pathologic, and imaging characteristics of 83 cases of PRNHL reported in the last 20 years in the English literature so far. For this purpose, all the published cases of the primary non-Hodgkin’s lymphoma of kidney were reviewed via a search in PubMed, Scopus, and Google Scholar, (1999–2019), using the keywords of “Primary renal lymphoma” and “Non-Hodgkin’s lymphoma and kidney,” “renal Non-Hodgkin’s lymphoma,” “renal lymphoma,” and “lymphoma and kidney.” There were 83 cases in the published English literature which were reviewed for this article. There was some missing information in some cases which has been recorded as “not reported.”

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Primary renal non-Hodgkin’s lymphoma: A narrative review of literature

2021

View full text Add to dashboard Cite

show abstract

“…Case reports and case series reporting on actual treatment of NHL patients on HD are shown in Table 1 (rituximab, CVP, and CHOP), 2,3,6,10‐35 Table 2 (various other regimens), 10,19,25,34‐51 and Table 3 (stem cell transplantation), 34,52‐54 and are discussed below. Recommendations on individual drug administrations are summarized in Table 4 3‐5,9‐11,19,25,38,39,43‐46,55‐60 .…”

Section: Individual Treatment Methodsmentioning

confidence: 99%

Chemotherapy for non‐Hodgkin lymphoma in the hemodialysis patient: A comprehensive review

Yasuda

Komatsu

2021

Cancer Science

View full text Add to dashboard Cite

Chemotherapy for non‐Hodgkin lymphoma (NHL) in the hemodialysis (HD) patient is a challenging situation. Because many drugs are predominantly eliminated by the kidneys, chemotherapy in the HD patient requires special considerations concerning dose adjustments to avoid overdose and toxicities. Conversely, some drugs are removed by HD and may expose the patient to undertreatment, therefore the timing of drug administration in relation to HD sessions must be carefully planned. Also, the metabolites of some drugs show different toxicities and dialysability as compared with the parent drug, therefore this must also be catered for. However, the pharmacokinetics of many chemotherapeutics and their metabolites in HD patients are unknown, and the fact that NHL patients are often treated with distinct multiagent chemotherapy regimens makes the situation more complicated. In a realm where uncertainty prevails, case reports and case series reporting on actual treatment and outcomes are extremely valuable and can aid physicians in decision making from drug selection to dosing. We carried out an exhaustive review of the literature and adopted 48 manuscripts consisting of 66 HD patients undergoing 71 chemotherapy regimens for NHL, summarized the data, and provide recommendations concerning dose adjustments and timing of administration for individual chemotherapeutics where possible. The chemotherapy regimens studied in this review include, but are not limited to, rituximab, cyclophosphamide + vincristine + prednisolone (CVP) and cyclophosphamide + doxorubicin + vincristine + prednisolone (CHOP)‐like regimens, chlorambucil, ibrutinib, bendamustine, methotrexate, platinum compounds, cytarabine, gemcitabine, etoposide, ifosfamide, melphalan, busulfan, fludarabine, mogamulizumab, brentuximab vedotin, and 90Y‐ibritumomab tiuxetan.

show abstract

A 64‐year‐old male with primary diffuse renal large B‐cell non‐Hodgkin lymphoma: A rare case report

Haydar,

Sleiay,

Alabdullah

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageIn the context of lymphoma, it is of paramount importance to perform subsequent Positron Emission Tomography‐Computed Tomography (PET‐CT) scans to ensure the comprehensive eradication of neoplasms.AbstractPrimary renal diffuse tumors constitute less than 1% of all renal neoplasms. Among these, diffuse renal large B‐cell lymphoma is an exceedingly rare extranodal lymphoma. A 64‐year‐old male presented to the Department of Urology with complaints of persistent left flank discomfort for a duration of 2 weeks. Additionally, he reported generalized weakness, fatigue, and symptoms indicative of lower urinary tract obstruction, such as discomfort in the left testicle and dysuria. Ultrasound imaging revealed an echogenic structure with thickened, reactive walls and a turbid fluid core, located in the left flank, proximal to the lower pole of the kidney. This structure was subsequently identified as diffuse renal large B‐cell lymphoma. For the diagnosis of large B‐cell lymphomas, it is imperative that a proficient hematopathologist performs a comprehensive examination of the tumor tissue, preferably utilizing an excisional biopsy. The categorization of lymphoma requires specialized tests such as immunohistochemistry, flow cytometry, fluorescence in situ hybridization (FISH), and molecular testing. In instances where a renal mass is detected, healthcare professionals should consider performing a biopsy. In lymphoma cases, follow‐up Positron Emission Tomography‐Computed Tomography (PET‐CT) scans are crucial to confirm the complete eradication of the tumor.

show abstract

Primary renal diffuse large B-Cell lymphoma causing haemodialysis-dependent nephromegaly in a child

Cited by 10 publications

References 16 publications

Primary renal non-Hodgkin’s lymphoma: A narrative review of literature

Primary renal non-Hodgkin’s lymphoma: A narrative review of literature

Chemotherapy for non‐Hodgkin lymphoma in the hemodialysis patient: A comprehensive review

A 64‐year‐old male with primary diffuse renal large B‐cell non‐Hodgkin lymphoma: A rare case report

Contact Info

Product

Resources

About